The accumulation of angiostatin-like fragments in human prostate carcinoma

Clinical Cancer Research

Volumn 7, Issue 9, 2001, Pages 2750-2756

  Migita, T ^a   Oda, Y ^a   Naito, S ^a   Morikawa, W ^a   Kuwano, M ^a   Tsuneyoshi, M ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ANGIOSTATIN LIKE FRAGMENT; ANTIBODY; PLASMINOGEN; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CELL LYSATE; CYTOPLASM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA;

AGED; AGED, 80 AND OVER; ANGIOSTATINS; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMINOGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STAINING AND LABELING; TUMOR CELLS, CULTURED;

EID: 0034802828     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
2. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
3. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
4. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
5. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
6. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
7. Generation of angiostatin by reduction and proteolysis of plasmin
8. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells
9. Angiostatin generation by human pancreatic cancer
10. Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin
11. Angiostatin fragments in urine from patients with malignant disease
12. Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: Correlation with angiostatin generation and its clinical significance
13. In vitro tumor angiogenesis assays: Plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis
14. The primary structure of human plasminogen: Isolation of two lysine-binding fragments and one "mini-"plasminogen (MW, 38,000) by elastase-catalyzed-specific limited proteolysis
15. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
16. Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma
17. Histologic grading of prostate cancer: A perspective
18. Plasminogen: Purification from human plasma by affinity chromatography
19. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma
20. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin
21. Prostate specific antigen and Gleason grade: An immunohistochemical study of prostate cancer
22. Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma
23. Angiostatin expression in non-small cell lung cancer
24. The plasmin system in human colonic tumors: An immunofluorescence study
25. Detection of the plasmin system in human mammary pathology using immunofluorescence
26. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
27. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma
28. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
29. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: Lack of significance for microvessel density analysis
30. Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome
31. Human prostate-specific antigen: Structural and functional similarity with serine proteases
32. Antiangiogenic activity of prostate-specific antigen
33. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using Northern-blot analysis, in situ hybridization and immunohistochemical staining with monoclonal and bispecific antibodies
34. In situ hybridization of prostate-specific antigen mRNA in human prostate
35. The response of poorly differentiated prostatic tumors to staining for prostate specific antigen and prostatic acid phosphatase: A comparative study
36. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate
37. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: Prognostic implications
38. Immunoelectron microscopic localization of prostatic-specific antigen in human prostate by the protein A-gold complex
39. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, non-specific cross-reacting antigen. β-chorionic gonadotrophin, and prostate-specific antigen